|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910139118703321 |
|
|
Titolo |
Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, New Jersey : , : Wiley, , 2014 |
|
©2014 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-118-77816-2 |
1-118-77815-4 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (760 p.) |
|
|
|
|
|
|
Collana |
|
Wiley Series on Technologies for the Pharmaceutical Industry |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Drug Discovery |
Public-Private Sector Partnerships |
Drug development |
Public-private sector cooperation |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry |
2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People |
|
|
|
|